CD8A and neoplasm: Interestingly, mAWT020 not only selectively expanded and activated CD8+ T cells in “hot” tumor models (e.g., MC38 and CT26), but also demonstrated the ability to significantly elevate T-cell markers and activation signatures in the “cold” tumor model B16F10.